- Home
- JVA vs RDHL Comparison
JVA vs RDHL Comparison
Compare JVA & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JVA
- RDHL
- Stock Information
- Founded
- JVA 1971
- RDHL 2009
- Country
- JVA United States
- RDHL Israel
- Employees
- JVA N/A
- RDHL N/A
- Industry
- JVA Packaged Foods
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- JVA Consumer Staples
- RDHL Health Care
- Exchange
- JVA Nasdaq
- RDHL Nasdaq
- Market Cap
- JVA 14.7M
- RDHL 13.1M
- IPO Year
- JVA 2005
- RDHL N/A
- Fundamental
- Price
- JVA $2.95
- RDHL $8.10
- Analyst Decision
- JVA
- RDHL
- Analyst Count
- JVA 0
- RDHL 0
- Target Price
- JVA N/A
- RDHL N/A
- AVG Volume (30 Days)
- JVA 180.9K
- RDHL 26.7K
- Earning Date
- JVA 10-18-2024
- RDHL 10-15-2024
- Dividend Yield
- JVA N/A
- RDHL N/A
- EPS Growth
- JVA N/A
- RDHL N/A
- EPS
- JVA 0.20
- RDHL N/A
- Revenue
- JVA $76,111,698.00
- RDHL $3,707,000.00
- Revenue This Year
- JVA N/A
- RDHL $224.90
- Revenue Next Year
- JVA N/A
- RDHL $82.69
- P/E Ratio
- JVA $15.13
- RDHL N/A
- Revenue Growth
- JVA 17.27
- RDHL N/A
- 52 Week Low
- JVA $0.67
- RDHL $6.43
- 52 Week High
- JVA $3.88
- RDHL $82.00
- Technical
- Relative Strength Index (RSI)
- JVA 53.73
- RDHL 40.51
- Support Level
- JVA $2.69
- RDHL $7.95
- Resistance Level
- JVA $3.12
- RDHL $8.50
- Average True Range (ATR)
- JVA 0.26
- RDHL 0.59
- MACD
- JVA -0.07
- RDHL -0.13
- Stochastic Oscillator
- JVA 27.62
- RDHL 3.85
About JVA Coffee Holding Co. Inc.
Coffee Holding Co Inc is engaged in the business of wholesale coffee operations, including manufacturing, roasting, packaging, marketing and distributing roasted and blended coffees for private labeled accounts and its own brands, and it sells green coffee. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada and certain countries in Asia.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.